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The Unfolded Protein Response Increases Production of Pro-Angiogenic Factors
by Tumor Cell Lines
Abstract
The rapid growth and proliferation of tumor cells will be limited at a stage when they encounter
inadequate levels of oxygen and nutrient supply within the poorly vascularized tumor mass. These severe
conditions negatively affect the proper folding of nascent proteins in the endoplasmic reticulum (ER) and
lead to accumulation of unfolded protein within ER which is referred to as ER stress. Consequently, it will
trigger the unfolded protein response (UPR) signal pathway through ER membrane stress sensor proteins
including activating transcription factor 6 (ATF6), inositol-requiring 1 (IRE1) and PKR-like ER localized
kinase (PERK). The UPR is largely a cytoprotective response and is thought to contribute to tumor survival
in the face of inadequate nutrients and oxygen. Microarray analyses were conducted on Daoy, a human
medulloblastoma line that was treated with thapsigargin, which activates the UPR by depleting Ca2+ from
the ER. In addition to the expected UPR targets, we found that ER stress inducing agents led to the
transcriptional induction of several pro-angiogenic factors including vascular endothelial growth factor
(VEGF), fibroblast growth factor 2 (FGF2), interleukin 8 (IL-8) and angiogenin. Using quantitative real-time
PCR, we confirmed that a number of UPR inducing conditions (i.e., thapsigargin, tunicamycin, and no
glucose) up-regulated VEGF, IL-8 and Angiogenin transcripts and extended these finding to a rat glioma
line, a mouse fibroblast line and two human neuroblastoma lines. Our western blot and ELISA assay
demonstrated the protein and secretion levels of VEGF were also elevated in C6 cells under ER stress
condition.
To understand the mechanism by which ER stress triggers the up-regulation of pro-angiogenic factors, we
tested the transcription rate and mRNA half-life of VEGF under ER stress condition. Both are dramatically
increased by thapsigargin and glucose deprivation in C6 rat glioma cells. By chromatin IP experiments, we
found that XBP1 bound to the promoter region of VEGF gene in response to ER stress in C6 cells which
suggested that XBP1 may transactivate VEGF gene during UPR activation. After testing several stress
inducible kinases which have been shown to contribute to stabilize VEGF mRNA in different cell lines in
response to various stress conditions, we found that activation of both AMP-activating protein kinase
(AMPK) and p38 mitogen activating protein kinase (p38 MAPK) elevate VEGF mRNA level by increasing
its stability during ER stress. We also found that activation of JNK increase VEGF mRNA by increasing its
transcription in response to the UPR. These results suggest that ER stress may increase the production of
pro-angiogenic factors at multiple levels including increasing transcription of VEGF and stabilization of its
mRNA, thus contributing to tumor angiogenesis.
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ABSTRACT
The rapid growth and proliferation of tumor cells will be limited at a stage when
they encounter inadequate levels of oxygen and nutrient supply within the poorly
vascularized tumor mass. These severe conditions negatively affect the proper folding of
nascent proteins in the endoplasmic reticulum (ER) and lead to accumulation of unfolded
protein within ER which is referred to as ER stress. Consequently, it will trigger the
unfolded protein response (UPR) signal pathway through ER membrane stress sensor
proteins including activating transcription factor 6 (ATF6), inositol-requiring 1 (IRE1)
and PKR-like ER localized kinase (PERK). The UPR is largely a cytoprotective response
and is thought to contribute to tumor survival in the face of inadequate nutrients and
oxygen. Microarray analyses were conducted on Daoy, a human medulloblastoma line
that was treated with thapsigargin, which activates the UPR by depleting Ca2+ from the
ER. In addition to the expected UPR targets, we found that ER stress inducing agents led
to the transcriptional induction of several pro-angiogenic factors including vascular
endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2), interleukin 8 (IL-8)
and angiogenin. Using quantitative real-time PCR, we confirmed that a number of UPR
inducing conditions (i.e., thapsigargin, tunicamycin, and no glucose) up-regulated VEGF,
IL-8 and Angiogenin transcripts and extended these finding to a rat glioma line, a mouse
fibroblast line and two human neuroblastoma lines. Our western blot and ELISA assay
demonstrated the protein and secretion levels of VEGF were also elevated in C6 cells
under ER stress condition.
To understand the mechanism by which ER stress triggers the up-regulation of
pro-angiogenic factors, we tested the transcription rate and mRNA half-life of VEGF
under ER stress condition. Both are dramatically increased by thapsigargin and glucose
deprivation in C6 rat glioma cells. By chromatin IP experiments, we found that XBP1
bound to the promoter region of VEGF gene in response to ER stress in C6 cells which
suggested that XBP1 may transactivate VEGF gene during UPR activation. After testing
several stress inducible kinases which have been shown to contribute to stabilize VEGF
mRNA in different cell lines in response to various stress conditions, we found that
activation of both AMP-activating protein kinase (AMPK) and p38 mitogen activating
protein kinase (p38 MAPK) elevate VEGF mRNA level by increasing its stability during
ER stress. We also found that activation of JNK increase VEGF mRNA by increasing its
transcription in response to the UPR. These results suggest that ER stress may increase
the production of pro-angiogenic factors at multiple levels including increasing
transcription of VEGF and stabilization of its mRNA, thus contributing to tumor
angiogenesis.
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Chapter 1. Introduction
ER Stress and the Unfolded Protein Response
The endoplasmic reticulum (ER) regulates the synthesis and processing of nearly
all proteins that reside in, or pass through, the endomembrane system of a eukaryotic cell
(Hampton, 2000). This large group of proteins is delivered into the ER co-translationally
or post-translationally and get modified and properly folded by ER resident enzymes and
chaperons. Peptides that fail to fold correctly can be recognized and destroyed through
ER-associated degradation (ERAD). The unfolded protein response (UPR) is a
multifaceted signal transduction pathway that is activated in all eukaryotic organisms in
response to changes in the environment of the endoplasmic reticulum (ER) that adversely
affect protein folding and assembly in the secretory pathway (ER stress). The response is
generally thought to protect cells from the transient alterations that can occur in the ER
environment and serves to restore homeostasis in this organelle. Under extreme or
prolonged stress, apoptotic pathways can be activated to destroy the cell. Recent studies
reveal that in addition to protecting cells from adverse physiological conditions, the UPR
plays an essential role in the development and normal functioning of some tissues and
can be a major contributor to the pathology of some diseases.
Characteristics of the UPR
In 1977, GRP78 and GRP94 were first discovered as transformation-related
proteins that were later demonstrated to be up-regulated by glucose deprivation and rapid
metabolism (Pouyssegur et al., 1977; Shiu et al., 1977). Later, these two proteins were
independently identified as ER resident chaperones, which monitor and help the folding
and assembly of secreted and membrane-bound proteins (Bole et al., 1986; Hendershot et
al., 1988; Lee, 1992). The concept of the UPR pathway was originally described in late
1980s and early 1990s when the mammalian cells were found to respond to severe ER
conditions, such as altered pH, low levels of glucose or oxygen, or alterations in the
oxidizing state of the ER by up-regulating the resident ER molecular chaperones. All
these conditions perturb the normal folding and maturation of the secretory pathway
proteins in this organelle, and indeed the entire UPR pathway can be activated by simply
expressing a mutant protein that cannot fold properly in the ER (Kozutsumi et al., 1988).
While this signal transduction pathway is primarily designed to safeguard the ER, its
effects are extended to other organelles, and in extreme cases it protects the organism by
terminating cells experiencing acute or chronic ER stress (Ma and Hendershot, 2004; Xu
et al., 2005).
A number of changes in the normal ER environment can affect the folding of
newly synthesized protein. For instance, lowering the ER pH alters side chain charges on
polypeptides; glucose deprivation both interferes with the glycosylation of nascent
proteins and inhibits energy production; and decreased oxygen causes the ER
environment to become more reducing, which blocks the formation of disulfide bonds.
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When these post-translational modifications are inhibited, the nascent peptides cannot
achieve their correct mature conformation and the incompletely folded proteins
accumulate in the ER by quality control programs that prevent them from further
transport along the secretory pathway (Ellgaard and Helenius, 2003). A number of
pharmacological agents are routinely used to activate the UPR for experimental purposes
(Lee, 1992). For example, thapsigargin, an inhibitor of the ER Ca2+ ATPase, depletes ER
calcium, and tunicamycin prevents the addition of N-linked glycans to nascent ER
proteins. DTT and 2-β mercaptoethanol alter the oxidizing environment of the ER and
interfere with formation of disulfide bonds that normally stabilize the folding and
assembly of secretory pathway proteins, and 2-deoxyglucose (2-DG) mimics low glucose
conditions by competing with glucose and prevents both N-linked glycosylation and
energy production, which is required for protein folding (Helenius, 1994; Kornfeld and
Kornfeld, 1985). Finally, Brefeldin A, an inhibitor of intracellular protein transport,
causes proteins to accumulate in the ER and activate the UPR.
The UPR is thought to function primarily as a cytoprotective response that
protects cells from transient but frequent changes in their environment (Figure 1-1). The
hallmark of the response is the up-regulation of ER chaperones, which bind to unfolded
regions on proteins, act to prevent their aggregation and promote proper refolding if
stress conditions are alleviated. This aspect of the response is conserved in all organisms.
A second feature of UPR activation is a transient inhibition of protein synthesis
(Brostrom et al., 1996), which limits the load of unfolded proteins. Interestingly, the
block in protein translation is not specific to ER proteins and occurs in all metazoans. A
third component of the UPR is the expansion of the degradative capacity of the cell,
which allows for the disposal of unfolded proteins (Brodsky et al., 1999; Kostova and
Wolf, 2003) and is found in all eukaryotic organisms. ER-associated degradation (ERAD)
is a highly selective mechanism used for both regulated degradation of certain functional
ER resident proteins and for the removal of aberrant and unassembled proteins from the
ER. Another long recognized aspect of the UPR is the arrest of cells in the G1 phase of
cell cycle (Lee et al., 1986), which serves to protect the organism by inhibiting the
proliferation of cells that are experiencing stress. Finally, if ER stress persists or is
particularly severe, apoptotic pathways are initiated to eliminate the stressed cell. The
first three functions contribute to preventing the aggregation of unfolded proteins by both
limiting the load of unfolded proteins in the ER and increasing the concentration of
molecular chaperones to deal with existing proteins. They constitute the cytoprotective
functions of the UPR, whereas the arrest of cells in the G1 phase is considered to be both
protective to the cell and the organism. Activation of apoptosis hits the point where the
cytoprotective aspects of the response shift to cytodestructive ones in order to protect the
organism. Thus, the entire response can be considered a protective one that is first active
at the cellular level and later shifts to the organismal level. Where this threshold is set is
not currently well understood and appears to vary between cell types.
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Altered pH, low glucose and oxygen in mammalian cells

Unfolded protein accumulated in ER

IRE1
p

PERK

ATF6
p

Caspase 12/4
p

p
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Increase of ERAD

Apoptosis

Translation inhibition and
Cell cycle arrest

Up-regulation of ER
chaperones

Figure 1-1. ER stress and the unfolded protein response (UPR). ER localized UPR
transducers and the downstream responses they control. Four ER localized proteins have
been identified that monitor evidence of stress conditions in the ER lumen and upon
activation regulate the downstream responses. These include PERK (blue), an eIF-2α
kinase that is responsible for the transient inhibition of protein synthesis and cell cycle
arrest. There are two Ire1 homologues (green), Ire1α which is ubiquitously expressed and
Ire1β which is expressed in the gut epithelium. Activation of Ire1 leads to cleavage of
XBP-1, which in turn regulates components of the degradative machinery. The third
transducer is ATF6 (yellow), which up-regulates ER chaperones, and the fourth stress
sensor is caspase 12 in mouse and caspase 4 in human (pink), which activates apoptotic
programs.
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Components of the UPR Pathway
The UPR response occurs in all known eukaryotes. It was first delineated in yeast
which has a single ER stress transducer that activates the entire pathway. This pathway is
conserved in higher eukaryotes but is largely expanded.
To identify the components of the UPR pathway in yeast, a 22-bp cis-acting
element from BiP promoter (UPRE) was identified that was sufficient to confer ER
stress-induced regulation of a heterologous transcript (Mori et al., 1992). This element
was used in a genetic screen that led to the identification of Ire1 (Cox et al., 1993; Mori et
al., 1993), which was originally discovered as inositol-requiring gene 1 (Ire1). The
structure of Ire1 includes an N-terminal ER targeting sequence, a luminal “stresssensing” domain, a transmembrane domain, a cytosolic kinase domain, and a C-terminal
domain that possesses endonuclease activity (Sidrauski and Walter, 1997). Ire1 is
required for yeast survival during ER stress but not during normal cell growth (Cox et al.,
1993; Mori et al., 1993). The target of Ire1’s endonuclease activity is the HAC1 transcript,
which encodes a basic leucine zipper transcription factor (Cox and Walter, 1996). HAC1
mRNA is constitutively expressed but not translated due to the presence of a 252nucleotide intron that inhibits translation. Activated Irelp cleaves the HAC1 transcript at
either end of the intron and Rlg1p, a tRNA ligase, re-ligates the transcript in a
spliceosome-independent reaction (Sidrauski et al., 1996). The spliced HAC1 mRNA is
efficiently translated to produce Hac1p, a transcription factor that translocates to the
nucleus where it binds to UPREs in ER chaperone promoters and up-regulates these and
numerous other UPR targets (Travers et al., 2000).
Mammals have preserved the basic components of the yeast UPR and greatly
expanded it (Figure 1-2). Two Ire1 homologues exist in mammalian cells: IRE1α and
IRE1β, which possess the same functions as yeast Ire1p (Tirasophon et al., 1998; Wang
et al., 1998b). The only known target of Ire1’s endonuclease activity is the X-box protein
1 (XBP-1) transcript (Calfon et al., 2002; Yoshida et al., 2001), which encodes a protein
with a DNA binding domain but no transactivation domain in unspliced form. The
excision of 26 bases from the XBP-1 transcript by activated Ire1 changes the reading
frame of the C-terminus of XBP-1, and the spliced form of XBP-1 now encodes a protein
(XBP-1(S)) that has both a DNA binding domain and a transactivation domain (Calfon et
al., 2002; Yoshida et al., 2001). The remodeled XBP-1(S) regulates components of the
ERAD pathway, like EDEM (Yoshida et al., 2003), co-factors of the ER chaperone BiP,
including ERdj3 and ERdj4 (Lee et al., 2003), an regulator of PERK’s kinase activity,
p58IPK, which relieve misfolding protein in the ER (van et al., 2003; Yan et al., 2002),
and components of lipid synthesis that play a role in the expansion of ER membranes
during the differentiation of some secretory tissues (Sriburi et al., 2004).
Unlike yeast, in mammalian cells, a transient inhibition of protein synthesis
occurs during the UPR, which is achieved by phosphorylating the eukaryotic translation
initiation factor-2α (eIF-2α) through the activation of PERK (Harding et al., 1999; Shi et
al., 1998). This leads to the loss of cyclin D1 from cells (Brewer and Diehl, 2000),
causing a G1 arrest that prevents the proliferation of cells experiencing ER stress.
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Figure 1-2. Components of the mammalian ER stress response. The accumulation of
unfolded proteins in the ER leads to the activation of three ER membrane proteins Ire1
(green), PERK (blue), and ATF6 (yellow) that act as signal transducers. These three arms
of the response are largely cytoprotective and serve to regulate downstream targets which
are ultimately responsible for the up-regulation of ER chaperones, inhibition of
translation, cell cycle arrest, a number of other transcriptional responses including those
downstream of ATF6 (yellow oval), AFT4 (green oval) NFκB (navy oval), and XBP-1
(blue oval). If the stress is not resolved, caspase 12 is activated to initiate apoptosis.
(Adapted with permission from Liao, N. and Hendershot, L. M. (2007). The unfolded
protein response: contributions to development and disease. Cell Stress Proteins 4, 57-88).
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Paradoxically, the translation inhibition specifically activates the expression of activating
transcription factor 4 (ATF4), by suppressing the usage of several small open reading
frames at the 5 end of the transcript that overlaps with the true ATF4 start site (Harding et
al., 2000). ATF4 regulates a number of genes including those involved in metabolism and
energy production (Harding et al., 2003; Siu et al., 2002). In addition, ATF4 plays a role
in reversing the translation arrest by transactivating GADD34 (Ma and Hendershot, 2003;
Novoa et al., 2001), the regulatory subunit of the PP1 phosphatase that dephosphorylates
eIF-2α. This serves to reverse the translation arrest and contributes to apoptosis by
inducing the C/EBP-homologous protein (CHOP) (McCullough et al., 2001; Zinszner et
al., 1998). PERK is also required for NF-κB activation (Jiang et al., 2003), which upregulates anti-apoptotic proteins like BCL2 during ER stress. Thus, PERK sits at the
crossroad of both survival and death signals.
Using a one-hybrid screen to identify proteins that bound to the ER stress
regulated element (ERSE) found in ER chaperone promoters, Mori’s group identified
ATF6, a transcription factor that is synthesized as an ER-localized transmembrane
protein, with a luminal stress sensing domain and a cytosolically oriented transcription
factor domain (Haze et al., 1999). In response to ER stress, ATF6 is transported to the
Golgi, where it is cleaved by the Golgi-localized S1P and S2P proteases (Ye et al., 2000),
releasing the cytosolic transcription-factor domain. ATF6 up-regulates ER chaperones
such as BiP, GRP94, and calreticulin, and folding enzymes like peptidyl-prolyl isomerase
B (PPIase B) and protein disulfide isomerase (PDI) (Yoshida et al., 1998). ATF6 also
serves to up-regulate the XBP-1 transcript (Yoshida et al., 2001).
If ER stress conditions are not resolved, apoptotic pathways are activated. In
mouse, procaspase-12 is localized to the cytosolic face of the ER membrane and is
activated in response to ER stress (Nakagawa et al., 2000) by IRE1-dependent
mechanisms involving calpain activation (Nakagawa and Yuan, 2000). Although the
human caspase-12 gene contains several missense mutations and clearly cannot have a
role in UPR-induced apoptosis, recent data indicate that caspase-4 in humans is
homologous to murine caspase-12 and is activated in an ER-stress-specific manner,
indicating that it might be the human caspase-12 orthologue (Hitomi et al., 2004).

Angiogenesis and Tumor Neovascularization
Angiogenesis is a physiological process involving the growth of new blood
vessels from pre-existing vessels which occurs in growth and development, as well as in
wound healing process. During tumor progress, new blood vessel formation is critical to
maintain the nutrient supply for a tumor to keep growing aggressively. Thus, it is a
critical step in the transition of tumors from a dormant state to a malignant state which
was first described as “tumor angiogenic switch” by Dr. Judah Folkman in 1971.
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Angiogenesis in Development and Wound Healing Process
The adult vasculature is derived from a network of blood vessels that is initially
created in the embryo by vasculogenesis, a process in which vessels are formed de novo
from endothelial cell precursors termed angioblasts (Risau, 1997). During vasculogenesis,
angioblasts proliferate and construct a primitive network of vessels known as the primary
capillary plexus. The endothelial cell lattice created by vasculogenesis then serves as a
scaffold for angiogenesis (Papetti and Herman, 2002). After the primary capillary plexus
is formed, it is remodeled by the sprouting and branching of new vessels from preexisting
ones in the process of angiogenesis.
Most normal angiogenesis occurs in the embryo, where it establishes the primary
vascular system as well as an adequate vasculature for growing and developing organs
(Folkman, 1995). Angiogenesis occurs in the adult during the ovarian cycle and in
physiological repair processes such as wound healing (Klagsbrun and D'Amore, 1991).
Maturation and remodeling of newly formed microvessels is accomplished by the
coordination of several diverse processes in the microvasculature (Klagsbrun and Moses,
1999). Angiogenesis is initiated by an increased permeability of existing blood vessel by
removing pericytes from the branching vessel and degrading the basement membrane and
extracellular matrix of endothelial cells. The new matrix synthesized by stromal cells,
coupled with soluble growth factors, then promotes the migration and proliferation of
endothelial cells. After sufficient proliferation, the endothelial cells arrest in a monolayer
and form a tubelike structure. Pericytes and smooth muscles cells then are recruited to the
surface of the endothelium and vessel is uncovered by pericytes regression. Blood flow is
then established in the new vessel. The process is tightly controlled by a delicate balance
of pro- and anti-angiogenic factors (Table 1-1).
Tumor Neovascularization
In tumor progression, neovascularization, also known as tumor angiogenesis is an
essential step for cancer cells to overcome the limited blood supply and further proliferate
themselves. Growth of solid tumors beyond 1–2mm in diameter requires the induction
and maintenance of a new blood supply. Failure to induce an angiogenic response may
result in tumor ‘dormancy’ and interference with an established blood supply leads to
necrosis or apoptosis of tumor cells and tumor regression (Folkman, 1996; Holmgren et
al., 1995).
Under normal physiological condition, anti-angiogenic factors, also known as
angiostatic factors, outweigh pro-angiogenic factors and angiogenesis does not occur.
However, during tumor formation, pro-angiogenic factors are induced and highly
expressed by tumor cells and their stromal partners. Their over-expression alters the
balance and triggers the “angiogenic switch” of the tumor. Although a tumor may elicit
the formation of blood vessels from preexisting capillaries in a process very similar to
normal angiogenesis, tumor-induced blood vessels are structurally abnormal. Most of
them lack functional pericytes (Benjamin et al., 1999) and have exceptional high
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Table 1-1. Major stimulators and inhibitors of angiogenesis.

Pro-angiogenic
factors

Anti-angiogenic
factors

Biological functions

Angiostatin

EC proliferation ↓, EC
apoptosis ↑, EC
migration ↓, tube
formation ↓, angiostatic
in vivo

FGF family

EC proliferation,
Plasminogen activator
↑, EC migration,
angiogenesis in vivo

Endostatin

EC proliferation ↓, EC
apoptosis ↑, EC
migration ↓, inhibition
of MMPs, angiostatic in
vivo

Angiopoietin1

EC sprouting, vessel
stabilization

Thrombospondin

EC migration ↓, EC
apoptosis ↑, angiostatic
in vivo

Angiopoietin2

EC proliferation, EC
migration, EC sprouting
in presence of VEGF

PDGF

Chord formation in
vitro, proliferation of
SMC and PC, vessel
stabilization

Angiogenin

EC proliferation

VEGF family

Biological functions

Permeability ↑,
Plasminogen activator
↑, EC proliferation ↑,
EC apoptosis ↓, EC
migration, angiogenesis
in vivo

CXC
chemokines
without ELR
motif
PEDF

(Continued)
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Inhibition of FGF and
VEGF165 bind to their
receptors, angiostatic in
vivo
EC migration ↓, EC
apoptosis ↑, angiostatic
in vivo

Table 1-1 (continued).

Pro-angiogenic
factors
CXC chemokines
with ELR motif

Integrins

Anti-angiogenic
factors

Biological functions

Biological functions

EC proliferation,
EC migration
EC attachment, EC
migration, EC
apoptosis ↓,
essential for FGF
induced
angiogenesis

EC=endothelial cells; SMC=smooth muscle cells; PC=pericytes; VEGF=vascular
endothelial growth factor; FGF=fibroblast growth factor; PDGF=platelet derived growth
factor; PEDF=pigment epirghelium dirived factor
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permeability due to the presence of fenestrae and transcellular holes and lack of a
complete basement membrane (Carmeliet et al., 1996). In addition, tumor vessel walls
may be made up of both endothelial cells and tumor cells (Cheresh, 1987). These
structural abnormalities in tumor vessels reflect the pathological nature of their induction,
yet their ability to support cell growth also underlies the use of physiological mechanisms
of angiogenesis that tumors commandeer for their propagation.
The induction of new blood vessel growth by a tumor is mediated through the
action of many pro-angiogenic factors including VEGF, FGF2, IL-8, Angiopoietin2,
Angiogenin. These factors are regularly expressed at a very low level. However, in tumor
cells under hypoxia condition, they are highly induced. The mechanism by which a tumor
induces neovasularization is shown in Figure 1-3.

Contribution of the UPR to Tumor Progress
The UPR Is Activated in Solid Tumors of Both Human Patients and Transgenic Mice
Once genotoxic alterations occur that essential to the development of a cancer cell,
the tumor encounters an inadequate environment that can become growth limiting. These
conditions lead to the activation of cytoprotective responses including the hypoxia
induced response (Graeber et al., 1996; Hockel and Vaupel, 2001a; Hockel and Vaupel,
2001b)and the UPR (Feldman et al., 2005; Ma and Hendershot, 2004). Primary
hepatocellular carcinomas show evidence of XBP-1 and ATF6 activation (Shuda et al.,
2003), and downstream targets like CHOP, BiP, GRP94, and GRP170 (also known as
ORP150) have been reported to be up-regulated in breast tumors (Fernandez et al., 2000),
hepatocellular carcinomas (Shuda et al., 2003), gastric tumors (Song et al., 2001), and
esophageal adenocarcinomas (Chen et al., 2002). One study reported that BiP was
overexpressed more frequently in the higher-grade, estrogen-receptor-negative tumors
than in lower-grade, estrogen-receptor-positive tumors (Fernandez et al., 2000),
suggesting that UPR activation is correlated with a clinically more aggressive phenotype.
In support of this, a fibrosarcoma cell line that was engineered to have lower levels of
BiP formed tumors initially, but they were rapidly resolved (Jamora et al., 1996). In two
more recent studies, researchers found that transformed PERK null MEFs produced much
smaller tumors that exhibited higher levels of apoptosis in hypoxic areas than wild-type
MEFs (Bi et al., 2005), and that XBP-1 null MEFs and XBP-1–knockdown cells did not
form tumors in mice, even though their growth rate and secretion of VEGF were similar
to wild-type cells (Romero-Ramirez et al., 2004). Since both PERK and XBP-1 activation
are specific to the UPR pathway, this evidence suggests that not only is the UPR
activated but that it can play an essential role in tumorigenesis.
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Figure 1-3. Mechanism of tumor angiogenesis. A: schematic of tumor blood vessel
(green, normal tumor cells; black, necrotic tumor cells). Notice the thin walls, tortuous
shape, absence of pericytes, and variations in diameter. Numerous gaps or fenestrae are
found between endothelial cells. The vessel wall is mosaic and can consist of both tumor
cells as well as endothelial cells. B: model of tumor-induced neovascularization. In i, an
initially avascular tumor grows until inner regions become hypoxic and upregulate
production of angiogenic factors such as VEGF, FGF and interleukin (IL)-8. In ii, a
tumor grows on an existing blood vessel. Soon the tumor induces Ang2 expression in the
preexisting vessel, and it regresses due to endothelial cell apoptosis. The tumor is now
avascular, and by upregulating angiogenic factors as in i, it induces the production of a
new blood supply. (Reprinted with permission from Yancopoulos, G. D., Davis, S., Gale,
N. W., Rudge, J. S., Wiegand, S. J., and Holash, J. (2000). Vascular-specific growth
factors and blood vessel formation. Nature 407, 242-248.)
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Tumor Establishment and Survival
Many studies have focused on the signal transduction pathway activated in
response to hypoxic conditions and demonstrated that hypoxia-inducible factor1α (Hif1α)
plays a critical role in tumor growth and angiogenesis (Pugh and Ratcliffe, 2003;
Semenza et al., 2000). Several recent studies provide evidence to suggest that the UPR
and Hif1α pathways are related to each other and may interact to regulate downstream
targets. For instance, cells cultured under hypoxic conditions activated PERK (Koumenis
et al., 2002), leading to eIF2α phosphorylation and expression of both ATF4 and
GADD34 (Blais et al., 2004), suggesting that this branch of UPR is fully activated by
hypoxia. Hypoxia can also lead to activation of NFκB through a phosphorylationmediated degradation of IκB (Koong et al., 1994), and more recent studies have shown
that ER stress activates NFκB through a PERK dependent loss of IκB (Jiang et al., 2003).
Suggesting that multiple mechanisms for NFkB activation may be employed in a tumor
cell, it represents a possible point of synergy in the activation of this important antiapoptotic protein. CHOP, a pro-apoptotic factor, is also up-regulated by PERK. It is
presently unclear if these represent opposing effects on cell survival or if the dismantling
of apoptotic machinery that is a common feature to the transformation process interferes
with the CHOP effect in tumor cells. Indeed, a number of the pro-apoptotic components
that are activated during ER stress converge on the caspase 3/9 pathway, which is often
mutated or disabled in tumor cells (Soung et al., 2004), and the down-regulation of Bcl2
by CHOP maybe countered by the NFκB’s activation of anti-apoptic factors like c-IAP1
and c-IAP2 (Wang et al., 1998a) or its suppression of targets like PTEN (Vasudevan et al.,
2004).
Some targets are regulated differently by the two pathways. For example, the proapoptotic tumor suppressor p53 is stabilized in response to hypoxia through a reduction
in the level of MDM2, which targets p53 for proteasomal degradation (Alarcon et al.,
1999). However, during ER stress, glycogen synthase kinase-3β (GSK3β) is activated
and phosphorylates p53, which accelerates its degradation (Qu et al., 2004). As hypoxia
condition can both induce the UPR due to inhibition of disulfide bond formation, and
induce the classic hypoxia induced pathway through Hif1α/2α, it is important to clarify
which of these two pathways is dominant in cancer cells that retain p53 function and have
activated both pathways.
Effect of UPR Activation on Angiogenesis
Tumors respond to their inadequate vascularization by secreting the proangiogenic factor, VEGF ((Ferrara and vis-Smyth, 1997). Recent studies demonstrate that
in addition to its well characterized induction via Hif1α transactivation (Poellinger and
Johnson, 2004; Semenza, 2001), VEGF is also up-regulated by the UPR through an
ATF4-dependent pathway (Roybal et al., 2004). Furthermore, its processing in the ER
and secretion is controlled by GRP170, an ER chaperone that is up-regulated during both
ER stress (Lin et al., 1993) and hypoxia (Ikeda et al., 1997; Tamatani et al., 2001).
GRP170 increases the resistance of cells to hypoxia (Ozawa et al., 1999), and tumors
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cells that were manipulated to express high levels of GRP170 showed enhanced secretion
of VEGF, whereas decreasing the amount of GRP170 led to ER retention of VEGF
(Ozawa et al., 2001). When these cells were used in xenograft studies, the tumors
expressing low levels of GRP170 grew very poorly in animals, whereas cells that
overexpressed GRP170 produced larger tumors than the parental line (Ozawa et al.,
2001).
UPR Alters Sensitivity of Tumors to Chemotherapeutic Agents
In addition to a role in promoting tumor growth, there are a number of studies to
suggest that UPR activation in tumors might alter their sensitivity to chemotherapy. The
in vitro treatment of cultured cells with drugs that activate the UPR increases their
resistance to topoisomerase II (topo II) poisons (Hughes et al., 1989), which is thought to
occur via a UPR-mediated decrease in topo II levels (Gosky and Chatterjee, 2003; Shen
et al., 1989; Yun et al., 1995). Other studies have shown that the increased levels of BiP
that occur during UPR activation can result in the relocalization of BiP to the cytosol
where it binds caspase7 and caspase12 and prevents their activation in response to some
chemotherapeutic agents (Rao et al., 2002; Reddy et al., 2003). Activation of the UPR
has also been shown to up-regulate P-glycoprotein (Ledoux et al., 2003), which induces
multiple drug resistance. However, UPR activation can also increase the sensitivity of
some tumors to DNA cross-linking agents, like cisplatin (Chatterjee et al., 1997; Yamada
et al., 1999). A recent study reported that cisplatin is a potent UPR activator and induces
a calpain-dependent activation of caspase-12 (Mandic et al., 2003). Changes in the level
of any of the components of the DNA repair system in response to UPR activation could
also contribute to the increased sensitivity to these agents, although there are currently no
data to support this hypothesis. Together these studies suggest that it may be important to
couple information on UPR activation in tumors with treatment choices.

Project Rationale and Significance
As increasing evidence showed UPR activation in various solid tumors, it is
important to understand what role the UPR plays in tumor progression. In my initial
microarray studies on a human medulloblastoma line treated with the UPR inducer
thapsigargin, I observed that four pro-angiogenic factors – VEGF, IL-8, FGF2 and
Angiogenin were up-regulated. This result leads us to further investigate the relation
between UPR activation and the induction of angiogenesis in tumors. Two major aspects
of the role of the UPR in the regulation of proangiogenic factors will be investigated.
First, I will verify the microarray data and establish whether these genes are also induced
by other agents that affect folding in the ER and determine if this occurs in other types of
tumor cells. Second, I will determine the mechanism(s) leading to increased expression
of these genes during UPR activation.
Knowledge of the role of the UPR in tumor neovascularization will facilitate our
understanding of the effect of UPR activation in tumorigenesis. With the potential for
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designing inhibitors of oncogenic promoting factors in the UPR, it may be possible to use
this information to increase the efficacy of available anti-angiogenic drugs and perhaps to
design new ones.

Specific Aims
The main aim of this project is to address the role of the unfolded protein
response (UPR) in regulating the expression of pro-angiogenic, with the long term goal
being to determine to what extent the UPR contributes to angiogenesis. After a cancer
cell arises from series of genotoxic alterations, the rapid growth and proliferation of
tumor will be limited at a stage when it encounters inadequate levels of oxygen and
nutrients within the poorly vascularized tumor mass. In cultured cells, these severe
conditions lead to the activation of cellular stress responses including the UPR which is
trigged by the physiological environment alteration of endoplasmic reticulum, a condition
known as ER stress (Lee, 1992). Indeed, there are in vivo data to demonstrate that solid
tumors can respond to their insufficient environment by activating at least some elements
of the UPR. To resolve insufficient vascularization and re-gain the access to oxygen and
nutrients, tumor cells and their stromal partners secrete pro-angiogenic factors which
coordinately activate proliferation of endothelial cells and promote tumor angiogenesis.
In our preliminary studies, we observed that four important pro-angiogenic factors –
VEGF, FGF2, IL-8 and Angiogenin – are up-regulated during UPR activation in several
tumor cell lines. During the course of my studies, several publications reported VEGF
and IL-8 are up-regulated by the UPR at both mRNA and secretion level. This implied
that the UPR may play an important role in promoting tumor angiogenesis by regulating
the levels of these pro-angiogenic factors during tumor progress. Therefore, based on
these previous data, I addressed the following issues in the next chapter.
Aim 1. Characterize the Effect of UPR Activation on Regulating Pro-angiogenic
Factors in Different Tumor Cell Lines
First, I will establish whether the up-regulation of transcripts of pro-angiogenic
factors occurs in response to other UPR inducers and assess how the level of induction
compares to that observed with hypoxia. Second, I will determine whether induction of
these genes occurs in multiple cell types. And third, I will compare the magnitude of
VEGF secretion in response to UPR activation versus hypoxia.
Aim 2. Determine How the UPR Regulates the mRNA Levels of These Factors
First, I will determine whether the increase of mRNA levels of VEGF factors are
due to transcription activation or a result of increased mRNA stability. Second, I will
determine which branch(es) and what downstream target(s) of the UPR are responsible
for regulating the transcription. And third, I will determine which branch(es) and what
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downstream target(s) of the UPR are responsible for the increased stability of VEGF
mRNA.
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Chapter 2. The Unfolded Protein Response Increases Levels of
Pro-angiogenic Factors in vitro
Introduction
Recently, the UPR signal pathway has been shown to be activated in tumors of
both human patients and mouse models. Therefore, it is important to understand how
UPR activation affects tumor growth and response to therapeutic intervention. Many
aspects of the UPR are cytoprotective, and several studies indicate that activation of the
UPR may have a crucial role in tumor growth. However, prolonged activation of the
response can initiate apoptosis, which could serve to protect the host. At present, it is
unclear where this balance lies in tumor development. In addition, activation of the UPR
in cell culture has been shown to alter the chemosensitivity of tumors, making them more
sensitive to certain drugs and more resistant to others, again underscoring the fact that
activation of the UPR can lead to contradictory consequences for tumors.
We started the project by testing the extent of the UPR in the Daoy
medulloblastoma cell line which can be used in xenograft studies. Micro-array analysis
demonstrated that the expected UPR downstream targets were up-regulated when cells
were treated with the ER stress inducer thapsigargin, which poisons the ER calcium
ATPase and rapidly depletes calcium from the ER, which is essential for the proper
folding of many secretory pathway proteins. Unexpectedly, we also found that several
pro-angiogenic factors such as VEGF, FGF2, IL-8 and Angiogenin were also increased
by ER stress treatment. Through real-time PCR assay, I verified the induction of these
pro-angiogenic factors in Daoy cells and extended these findings to other tumor cell lines.
In addition, Western Blot and ELISA assays showed that the secretion of VEGF protein
was also increased dramatically during ER stress to levels even higher than those
observed with hypoxia. In this chapter, I will describe how I conducted the experiments
to test the increase of pro-angiogenic factors by the UPR and what has been done to
investigate the mechanism by which the UPR increase VEGF mRNA level in vitro.

Materials and Methods
Reagents and Tissue Culture
Actinomycin D (Act. D), LY294002, PD98059, SB203580, SP600580, cobalt
chloride (CoCl2), tunicamycin (Tm) and thapsigargin (Tg) were purchased from SigmaAldrich. Compound C was obtained from Cell Signaling Technology. DMEM and RPMI
media, both with and without glucose came from Invitrogen.
NIH3T3 mouse fibroblast cells, C6 rat glioma cells and Daoy human
medulloblastoma cells were cultured in DMEM supplemented with 10% heat-inactivated
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fetal bovine serum (FBS) at 37°C with 95% air and 5% CO2. NB-1691 and SK-N-AS
human neuroblastoma cell lines were regularly cultured in RPMI supplemented with 10%
heat-inactivated FBS at 37°C with 95% air and 5% CO2. As a more physiological method
of activating the UPR, cells were cultured in glucose-free DMEM or RPMI supplemented
with 10% heat-inactivated and dialyzed FBS at 37°C with 95% air and 5% CO2. Hypoxic
responses were induced by culturing cells in the same regular media at 37°C with 94%
nitrogen, 1% O2 and 5% CO2.
Microarray Analysis
Total RNA isolated using RNeasy kits (Qiagen) was prepared for hybridization to
Affymetrix HG-U133Plus2 chips following the Affymetrix one-cycle labeling protocol
(http://www.affymetrix.com/support/technical/manual/expression_manual.affx). After
purification, the cDNA was used as template to incorporate biotin-label into anti-sense
cRNA by using the T7 RNA polymerase and biotin-labeled nucleotide. Fifteen
micrograms of the biotin-labeled cRNA were fragmented by heating and metal induced
hydrolysis, added to a hybridization cocktail containing probe array controls and blocking
agents (BSA and herring sperm DNA), then incubated overnight at 45°C on a GeneChip
array. Following hybridization, the arrays were automatically washed in a GeneChip
Fluidics Station 450 using high stringency conditions to remove non-hybridized labeled
cRNA. Experiments were done in duplicate. Expression signals for each probeset were
calculated using the Affymetrix GeneChip Operating Software (GCOS version 1.4).
Relative fold change of each gene was calculated by normalizing data from the
thapsigargin treated group to the control experimental condition. Mean value was
obtained from duplicated experiments.
Real-time PCR
Quantitative real-time PCR experiments were performed on the HT7900
Sequence Detection System (Applied Biosystems) with 40 amplification cycles.
Quantitative data were obtained using a standard curve method. Total RNA was extracted
from cells by using Quiagen RNAeasy Mini Kit. TaqMan® One-Step RT-PCR Master
Mix Reagents (from Applied Biosystems) were used to conduct the real-time PCR
reactions in 96-well plates. Commercial 18s rRNA primers/probe were used as the
internal control for all real-time PCR experiments. The following primers/probes were
used for individual target genes:
BiP (rat or mouse) forward primer, AGGAGACTGCTGAGGCGTAT; BiP (rat or
mouse) reverse primer, GCTGGGCATCATTGAAGTAA; BiP (human, rat or mouse)
probe, CTGCATGGGTAACCTTCTTTCCCAA. BiP (human) forward primer,
CTCAACATGGATCTGTTCCG; BiP (human) reverse primer,
CCAGTTGCTGAATCTTTGGA; BiP (human) probe,
TTCGAGTCGAGCCACCAACAAGA. CHOP (rat or mouse) forward primer,
GCGACAGAGCCAGAATAACA; CHOP (rat or mouse) reverse primer,
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ACCAGGTTCTGCTTTCAGGT; CHOP (rat or mouse) probe,
AACACTCTCTCCTCAGGTTCCGGC. CHOP (human) forward primer,
TCCTGGAAATGAAGAGGAAGA; CHOP (human) reverse primer,
CAGGGAGCTCTGACTGGAAT; CHOP (human) probe,
CACAAGCACCTCCCAGAGCCC. GRP170 (rat or mouse) forward primer,
GACAGGGTGGAGTCCGTATT; GRP170 (rat or mouse) reverse primer,
CAAACAGGCTGGATATGGTG; GRP170 (rat or mouse) probe,
TCTGGGCTATCCTCCACCAGGG. GRP170 (human) forward primer,
TTGGGCATGGTTCTCAATTA; GRP170 (human) reverse primer,
CTGGTTGAAGAAGACTGGCA; GRP170 (human) probe,
TGCAGAGCAGCCCATCAAGGA. Angiogenin (rat) forward primer,
GCAAGCATACAGGAGGGTCT; Angiogenin (rat) reverse primer,
CATCAAAGTGGACAGGCAAG; Angiogenin (rat) probe,
CCTTGCCGGTACCGAGCCTC. Angiogenin (mouse) forward primer,
GCCAGCTTTGGAATCTCTGT; Angiogenin (mouse) reverse primer,
AGAGTGGGAGGGATCACAAC; Angiogenin (mouse) probe,
CGATAAGCCCAGGCCCGTTG. Angiogenin (human) forward primer,
AGGAGCCTGTGTTGGAAGAG; Angiogenin (human) reverse primer,
AGCACGAAGACCAACAACAA; Anigiogenin (human) probe,
AACGCCCAGGCCCATCACC. FGF2 (rat or mouse) forward primer,
GCTGCTGGCTTCTAAGTGTG; FGF2 (rat or mouse) reverse primer,
TACTGCCCAGTTCGTTTCAG; FGF2 (rat or mouse) probe,
ACCAACTGGAGTATTTCCGTGACCG. FGF2 (human) forward primer,
TGGCTATGAAGGAAGATGGA; FGF2 (human) reverse primer,
ACTGCCCAGTTCGTTTCAGT; FGF2 (human) probe,
CCAACTGGTGTATTTCCTTGACCGG. IL-8 (human) forward primer,
AGGACAAGAGCCAGGAAGAA; IL-8 (human) reverse primer,
ACTGCACCTTCACACAGAGC; IL-8 (human) probe,
ACTTCCAAGCTGGCCGTGGC. VEGF (rat or mouse) forward primer,
CACTGGACCCTGGCTTTACT; VEGF (rat or mouse) reverse primer,
CTTCTGTCGTGGGTGCAG; VEGF (rat or mouse) probe,
CCATGCCAAGTGGTCCCAGG. VEGF (human) forward primer,
AGAAGGAGGAGGGCAGAATC; VEGF (human) reverse primer,
TCTCGATTGGATGGCAGTAG; VEGF (human) probe,
CATCCATGAACTTCACCACTTCGTGA. VEGF hnRNA (rat) forward primer,
AAGGTGAGTCCTCATGCTTGT; VEGF hnRNA (rat) reverse primer,
GTGCAATCTCGACCCTCATA; VEGF hnRNA (rat) probe,
TGGGTCCCTGTTGTCCCATTCC.
Western Blot and ELISA Assay
For Western Blot assay, cells were trypsinized for 5 minutes at 37°C. Complete
DMEM or RPMI with 10% FBS was used to inactivate trypsin at room temperature. Cell
pellets were centrifuged down, washed twice with cold PBS and stored in -80°C until
needed. Whole cell lysates were obtained by lysing cell pellets in RIPA cell lysis buffer
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(50 mM Tris-HCl (pH7.4), 150 mM NaCl, 1 mM PMSF, 1 mM EDTA, 5 µg/ml
Aprotinin, 5 µg/ml Leupeptin, 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS)
at 4°C for 15 minutes. Cell lysates were clarified by centrifugation at 14,000rpm for 30
minutes. After adding an equal volume of 2X of SDS reducing sample buffer (62.5 mM
Tris–HCl (pH 6.8), 10% glycerol, 5% b-mercaptoethanol, 2% SDS), samples were
denatured by heating at 90°C for 10 minutes. Proteins were separated by reducing SDS10% acrylamide gels, transferred to a PVDF membrane and probed with the indicated
primary antibody: Polyclonal rabbit-anti-BiP, anti-GRP170 and anti-CHOP antisera were
raised against hamster recombinant BiP, an N-terminal fagment of human recombinant
GRP170 or mouse recombinant CHOP respectively and have been described previously.
Polyclonal rabbit-anti-VEGF antisera was purchased from R&D systems.
VEGF ELISA assays were performed using a commercial kits specific for rat
VEGF (R&D Systems). Assays for each sample were performed in duplicate, and
readings were compared with standard curves obtained with the rat recombinant
VEGF165 that was provided.
Statistics
All real-time PCR experiments were performed in either duplicate or triplicate as
indicated in figure legends. Means and standard deviations of each sample were
calculated by Microsoft Excel. Data were normalized to the relative fold change
comparing to control sample. VEGF ELISA assay was performed in triplicate. Means and
standard deviations of each sample were calculated by Microsoft Excel.

Results
UPR Activation in Tumors of Transgenic Mouse Model and Human Patients
To investigate whether the UPR was induced in a genetic tumor model for
medulloblastoma, our lab performed in situ hybridization analysis on the slides of brain
tumors which spontaneously arise from Ptch+/- p18-/- transgenic mice. For expression of
BiP (downstream of ATF6), CHOP (downstream of PERK) and ERdj4 (downstream of
Ire1/XBP-1), we found that all three UPR target genes were induced, which demonstrate
that the UPR is activated in these solid tumors. In the mean time, an
immunohistochemistry analysis was done on human neuroblastoma patient samples. We
found evidence of CHOP expression in a number of samples from various tumor types,
including those from neuroblastomas (Figure 2-1), which indicates that at least the PERK
branch of the UPR is activated.
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Figure 2-1. Evidence of UPR activation in tumors. (A) Schematic of the three branches
of the UPR and a downstream target of each. (B) The brain of a Ptc1+/-, p18-/- mouse
that had developed a medulloblastoma was isolated, separated into the cerebrum (top)
and cerebellum (bottom), and fixed. After sectioning, tissue slices were stained with
H&E (a) or hybridized with probes for BiP (b), CHOP (c), or ERdj4 (d). Areas of
obvious tumor growth are indicated with arrows. (C) Slides from the human tumor tissue
array were stained with anti-CHOP. A portion of one slide containing a neuroblastoma is
expanded at two magnifications. The arrows identify the neuroblastoma cells in the
tissue core. ( D) Four different slides (right) representing xenografts of
rhabdomyosarcomas (a), brain tumors (b), Wilm’s and kidney tumors (c), and
osteosarcomas (d) were stained with anti-CHOP to detect UPR activation.
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Up-regulation of Pro-angiogenic Factors by UPR Activation in vitro
Since there is increasing evidence to show that at least some aspects of the UPR
are activated in solid tumors, we wished to more carefully examine this in xenograft
studies. We initially chose the Daoy human medulloblastoma for our studies and wished
to establish that this line maintained the ability to mount a full UPR in response to
conventional chemical UPR inducers. Daoy cells were treated with or without
thapsigargin which induces the UPR by depleting Ca2+ from ER and mRNA from these
cells were subjected to microarray analysis. We found that indeed all known targets of
the UPR were induced and that these represented downstream targets of all three
transducers (Table 2-1). Unexpectedly, we also observed several pro-angiogenic factors
were induced by thapsigargin treatment (Table 2-1). To further confirm these findings,
extend them to other UPR inducing agents, and compare the levels of induction to those
obtained with hypoxia, real-time PCR analyses were used to determine the mRNA levels
of these factors in the Daoy cell line as well as in several other tumor lines that are
routinely used in xenograft studies and a non-tumor line that has been extensively used to
study the UPR. These included the C6 rat glioma, the NB1691 and SKNAS human
neuroblastoma lines, and NIH3T3 cells. We found that although there was some variation
in the magnitude of gene induction between the different cell lines and in response to
different UPR inducers, three pro-angiogenic factors – VEGF, IL-8 and Angiogenin were
consistently up-regulated by ER stress (Figure 2-2 to Figure 2-6). FGF2 is up-regulated
only in Daoy cells, down-regulated in C6 and NIH3T3 cells, and not detectable in the two
neuroblastoma tumor lines which suggest that this pro-angiogenic factor may not be a
common UPR target. When the magnitude of induction of the various factors was
compared to that obtained with hypoxia, we found that their induction during ER stress
were equal or even higher than that under hypoxia. For instance, VEGF was induced to a
higher level by ER stress than by hypoxia in C6 and NIH3T3 cells and was equally
induced by ER stress and hypoxia in other cells. IL-8 was induced to a much higher level
by thapsigargin than by other stress conditions in all human cells. Since no IL-8 gene
exists in rodent cells, no signal was observed in C6 and NIH3T3 cells. We also tested the
level of intracellular protein and secretion of VEGF in response to UPR activation and
hypoxia in the C6 rat glioma line, which consistently showed the highest induction of
VEGF mRNA in response to ER stress. We found that both steady state cellular protein
levels (Western blot) and secretion (ELISA) of VEGF were highly induced by all three
methods of UPR induction (Figure 2-7). The induction level of VEGF secreted was
comparable to or even higher than that observed in the hypoxia treated cells. There was
also a difference in the magnitude of induction of UPR target genes in response to
different UPR inducers, which also varied between the different lines. This suggests that
the threshold for UPR activation may vary in response to different agents in a cell type
specific manner. Surprisingly, the magnitude of UPR activation in response to different
stressors did not always correspond to the magnitude of induction of pro-angiogenic
factors. For instance, no glucose condition was the best UPR inducer for C6 cells; while
VEGF level under thapsigargin stress is higher than that under no glucose. However,
Western Blot and ELISA assays showed that protein and secretion level of VEGF was
induced to the highest level by no glucose stress.
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Table 2-1. Characterization of the UPR in Daoy medulloblastoma cell line by microarray.

Gene

Fold ↑ 3hr

Fold ↑ 8hr

Pathway

BiP

5.4

10.1

ATF6

GRP94

4.2

5.5

ATF6

GRP170

3.0

6.1

ATF6

XBP1

4.3

4.6

ATF6

PDI

1.4

7.5

ATF6

HERP

22.6

24.3

ATF6/PERK

CHOP

36.8

34.3

ATF6/PERK

ERdj3

2.3

4.3

Ire1

ERdj4

8.6

16.1

Ire1

EDEM

1.7

4.0

Ire1

P58IPK

5.0

6.9

Ire1

ATF4

3.0

3.2

PERK

ATF3

7.0

4.5

PERK

GADD34

4.6

6.5

PERK

VEGF

2.7

5.5

????

FGF2

1.5

3.7

????

Angiogenin

1.5

5.2

????

IL-8

30.0

15.6

????
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C6
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NB-1691
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Figure 2-2. Induction of UPR targets in different cell lines. Cell lines of C6 rat glioma,
NIH3T3 mouse fibroblast, Daoy human medulloblastoma, NB-1691 and SK-N-AS
human neuroblastoma were treated with 100uM CoCl2, 1% O2 hypoxia (Hy), 2.5ug/mL
tunicamycin (Tm), 1uM thapsigargin (Tg) or no glucose media (No Glu) for 24 hours.
RNA was extracted for quantitative RT-PCR analysis on UPR targets BiP (blue), CHOP
(red) and GRP170 (yellow). All experiments were performed in triplicate. Data represent
the mean value ± SD.
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Figure 2-3. Induction of VEGF in different cell lines. Cell lines of C6 rat glioma,
NIH3T3 mouse fibroblast, Daoy human medulloblastoma, NB-1691 and SK-N-AS
human neuroblastoma were treated with 100uM CoCl2, 1% O2 hypoxia (Hy), 2.5ug/mL
tunicamycin (Tm), 1uM thapsigargin (Tg) or no glucose media (No Glu) for 24 hours.
RNA was extracted for quantitative RT-PCR analysis on VEGF. All experiments were
performed in triplicate. Data represent the mean value ± SD.
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Daoy

NB-1691

SK-N-AS

Figure 2-4. Induction of Angiogenin in different cell lines. Cell lines of C6 rat glioma,
NIH3T3 mouse fibroblast, Daoy human medulloblastoma, NB-1691 and SK-N-AS
human neuroblastoma were treated with 100uM CoCl2, 1% O2 hypoxia (Hy), 2.5ug/mL
tunicamycin (Tm), 1uM thapsigargin (Tg) or no glucose media (No Glu) for 24 hours.
RNA was extracted for quantitative RT-PCR analysis on Angiogenin. No signal was
observed in NIH3T3 cells. All experiments were performed in triplicate. Data represent
the mean value ± SD.
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Figure 2-5. Induction of FGF2 in different cell lines. Cell lines of C6 rat glioma, NIH3T3
mouse fibroblast, Daoy human medulloblastoma, NB-1691 and SK-N-AS human
neuroblastoma were treated with 100uM CoCl2, 1% O2 hypoxia (Hy), 2.5ug/mL
tunicamycin (Tm), 1uM thapsigargin (Tg) or no glucose media (No Glu) for 24 hours.
RNA was extracted for quantitative RT-PCR analysis on FGF2. No signal was observed
in SK-N-AS and NB-1691 cells. All experiments were performed in triplicate. Data
represent the mean value ± SD.
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Figure 2-6. Induction of IL-8 in different cell lines. Cell lines of C6 rat glioma, NIH3T3
mouse fibroblast, Daoy human medulloblastoma, NB-1691 and SK-N-AS human
neuroblastoma were treated with 100uM CoCl2, 1% O2 hypoxia (Hy), 2.5ug/mL
tunicamycin (Tm), 1uM thapsigargin (Tg) or no glucose media (No Glu) for 24 hours.
RNA was extracted for quantitative RT-PCR analysis on IL-8. The gene of IL-8 does not
exist in rats or mice. All experiments were performed in triplicate. Data represent the
mean value ± SD.
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Figure 2-7. Induction of VEGF protein synthesis and secretion. C6 cells were treated
with 100uM CoCl2, 1% O2 hypoxia (Hy), 2.5ug/mL tunicamycin (Tm), 1uM
thapsigargin (Tg) or no glucose media (No Glu) for 24 hours. (A) Cell lysates were run
on 12% SDS gel. Western Blot was performed with an antibody specific for VEGF.
Hsc70 signals serve as a control for protein loading. Western Blot was performed in
duplicate. Both have similar results represented here. (B) After treatment, conditioned
media were collected for ELISA analysis by commercial VEGF ELISA kit from R&D
systems. ELISA was performed in triplicate. Data represent the mean concentration ± SD.
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Mechanism of Increase of VEGF mRNA by UPR Activation
While the mRNA level of VEGF, IL-8 and Angiogenin were clearly increased
during UPR activation in our study, another group also found that VEGF and IL-8 were
induced in TSE human breast adenocarcinoma line by ER stress inducers such as
tunicamysin, glucose depriviation, A23187 and Brefeldin A (Marjon et al., 2004).
However, the mechanism of induction of pro-angiogenic factors is still not well
understood. A previous study showed ATF4 transcriptionally up-regulated VEGF by
using homocysteine treatment to induce ER stress (Roybal et al., 2004). On the other
hand, several groups showed that the induction of these factors in response to hypoxia or
glucose depriviation is in large part an increase in the stability of their mRNA (Levy et al.,
1995; Levy et al., 1996; Yun et al., 2005). Thus, an understanding of the mechanism of
UPR activation in regulating mRNA level of them is required. Here I performed several
experiments to test how VEGF, one of the most important pro-angiogenic factors in
tumor angiogenesis, is regulated during UPR activation in C6 rat glioma cells in vitro.
As a first step, I performed a time-course experiment to determine the kinetics of
VEGF mRNA induction. C6 cells were incubated in complete media or treated with
hypoxia, thapsigargin or no glucose for 3, 8, 16 or 24 hours. Total RNA was extracted
from cells, and quantitative real-time PCR was performed to determine the VEGF mRNA
levels in each sample. The data (Figure 2-8) showed that VEGF mRNA was induced as
early as 3 hour in response to ER stress or hypoxia and continued to increase through the
time course. I did not treat C6 cells with ER stress inducing agents or hypoxia for longer
than 24 hours, because the cells started dying after that point. Thus, in later experiments,
I treated the cells for no more than 12 hours, which gave me a strong induction of VEGF
while still keeping the C6 cells healthy.
The next step was to determine whether the increase in VEGF mRNA by the UPR
was due to transcriptional activation or to an increase in VEGF mRNA stability. To
measure the half-live of VEGF mRNA, an mRNA turnover experiment was performed.
C6 cells were untreated (Nt) or pre-treated with 1% O2 to induce hypoxic responses (Hy),
thapsigargin (Tg) or no glucose media (No Glu) for 6 hours. Next, 5 ug/ml actinomycin
D was added to the cultured cells to inhibit transcription. The cells were then incubated
for the indicated times, and total RNA was extracted. Quantitative real-time PCR was
performed to determine that amount of VEGF mRNA that remained. The result of this
experiment (Figure 2-9) showed that the half-life of VEGF in response to thapsigargin or
no glucose treatment was much longer than that observed under control conditions, while
its half-life in response to hypoxia was not significantly changed. This result
demonstrates that the increase of VEGF mRNA observed in response to UPR activation
is at least partially due to the stabilization of this message, while the higher VEGF
message level under hypoxia may be only due to transactivation of VEGF by a
transcription factor complex including Hif1α or Hif2α. At the 30 minute time point in
each of the treatment groups, I found that the levels of residual VEGF mRNA was even
increased under ER stress or hypoxia conditions while that under normal condition kept
unchanged. Our explanation is that the unspliced hnRNA would be spliced into matured
mRNA and transported into cytosol during this 30 minute period. It leads to the delayed
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Figure 2-8. Induction of VEGF mRNA under stresses. C6 cells were treated with normal
condition (Nt), 1% O2 (Hy), thapsigargin (Tg) or no glucose media (No Glu) for indicated
time periods. Total RNA was extracted for quantitative real-time PCR to test VEGF
mRNA. The experiment was performed in duplicate. Data represent the mean value ± SD.
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Figure 2-9. Decay of VEGF mRNA under stresses. C6 cells were pre-treated with
normal condition (Nt), 1% O2 (Hy), thapsigargin (Tg) or no glucose media (No Glu) for 6
hours. Actinomycin D (5 ug/mL) was added to block transcription. After indicated time
periods, total RNA was extracted from cells to perform quantitative real-time PCR to test
VEGF mRNA. The experiment was performed in duplicate. Data represent the mean
value ± SD.
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decrease of VEGF under regular condition. An increase of residual VEGF mRNA level
under ER stress and hypoxia then represents that the amount of VEGF hnRNA under
these conditions is much more than the amount of VEGF being degraded during the early
30 minutes period which implies that VEGF transcription rate may be increased in these
stress conditions.
The transcription rate of a gene can be measured by examining the level of
heterogeneous nuclear RNA (hnRNA), which exists only briefly before the introns are
removed and the pre-RNA is fully processed into mature mRNA. This method was first
described by Lipson and Baserga (Lipson and Baserga, 1989). To measure VEGF
hnRNA, I designed the real-time PCR primers derived from exon2 and intron3 so that
only hnRNA but not mRNA of VEGF would be amplified during the PCR reaction.
However, a well purified mRNA without any DNA contamination is required, because
genomic DNA can also be amplified by this primer pair and may cause a false signal
problem. C6 cells were untreated or treated with 1% oxygen, thapsigargin or no glucose
for 3, 8, 16 or 24 hours. Total RNA from each sample was extracted and treated with
RNase-free DNase to remove the genomic DNA contaminate. Then quantitative real-time
PCR was performed to determine the amount of VEGF hnRNA present. The result of this
experiment (Figure 2-10) showed that the transcription rate of VEGF continuously
increased during UPR activation or hypoxia treatment. This suggests that the increase of
VEGF mRNA under UPR activation is also partially due to transactivation of the VEGF
gene. As the experiment quantitiated VEGF hnRNA as a measure of the gene’s
transcription rate, I needed to demonstrate that these stress conditions did not negatively
affect the rate of VEGF hnRNA splicing. To test this, I did an experiment which is very
similar to mRNA decay assay. The only difference is that the decay of VEGF hnRNA
instead of mature VEGF mRNA was examined. The data (Figure 2-11) demonstrates that
the half life of VEGF hnRNA under different conditions is very similar. All undergo
turnover in less than a 30-minute period. This further validated the conclusion that the
VEGF gene is transactivated during UPR activation, and in C6 cells this rate was even
higher than that observed in response to hypoxia. Taken together, my data demonstrates
that the UPR contributes to increases in VEGF mRNA by two distinct methods:
transcriptional transactivation and reduced turnover.
To further determine which UPR downstream transcription factor contributes to
transactivation of the VEGF gene, we listed several UPR downstream transcription
factors that can be candidates to promote VEGF transactivation. Among these factors,
ATF6 is an ER transmembrane protein whose cytosolic domain is a transcription factor
and is activated during ER stress by cleavage from ER membrane and translocating into
nucleus (Ye et al., 2000). ATF4 is another ER stress induced transcription factor. Its
activation is through shifting its translation starting sites mediated by eIF2α
phosphorylation (Harding et al., 2000). XBP1 is a transcription factor which is expressed
in full lenth only under ER stress through reading-frame shift mediated by UPR activated
IRE1 endonuclease activity (Calfon et al., 2002; Yoshida et al., 2001). NFκB is an
important anti-apoptotic factor which is activated by the UPR through depleting its
inhibitor IκB (Jiang et al., 2003). Finally, Hif2α which is regularly activated during
hypoxia has been shown to be up-regulated by the UPR in our microarray assay. With the
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Figure 2-10. VEGF is transcriptionally up-regulated in response to the UPR. C6 cells
were treated with normal condition (Nt), 1% O2 (Hy), thapsigargin (Tg) or no glucose
media (No Glu) for indicated time periods. Total RNA was extracted for quantitative
real-time PCR to test VEGF hnRNA. The experiment was performed in duplicate. Data
represent the mean value ± SD.
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Figure 2-11. UPR activation does not significantly affect hnRNA splicing. C6 cells were
pre-treated with normal condition (Nt), 1% O2 (Hy), thapsigargin (Tg) or no glucose
media (No Glu) for 6 hours. Actinomycin D (5 ug/mL) was added to block transcription.
After indicated time periods, total RNA was extracted from cells to perform quantitative
real-time PCR to test VEGF hnRNA. The experiment was performed in duplicate. Data
represent the mean value ± SD.
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list of UPR downstream transcription factors, I used rVista to analyze and look for
potential binding sites for each factors. Interestingly, four of these five factors do have
their potential binding sequences found in the 8k up-stream promoter region of VEGF
gene of mouse, rat and human (Figure 2-12). Currently, we are trying to find evidence to
show that any of these factors really bind to these sites under ER stress condition by
using Chromotin IP method to test protein-chromosome interaction. Our recent data
showed that XBP-1 may bind to VEGF promoter at -1k and -5k region in response to ER
stress. We are currently validating these data and testing other binding sites of other
transcription factors.
Several kinases have been shown to stabilize VEGF mRNA in response to
different stresses such as hypoxia and glucose deprivation. In a recent study, scientists
found that AMPK was activated during glucose deprivation which contributes to the
increase of VEGF mRNA stability (Yun et al., 2005). Their research also suggests that
JNK may be the upstream kinase of AMPK. Interestingly, JNK has been shown to be
activated by IRE1 through TRAF2 during UPR activation (Urano et al., 2000). Another
kinase p38 MAPK, which has been shown to be activated by PERK during ER stress
(Liang et al., 2006), also increases mRNA stability of VEGF through an AMPK-p38
MAPK cascade in response to ischemic injury (Ouchi et al., 2005). In addition, p38
MAPK and PI3 kinase has been reported to activate ARE binding protein like HuR
(Winzen et al., 1999) which can stabilize VEGF mRNA. To determine which kinase
plays a role in increasing VEGF mRNA stability in C6 cells, I used specific kinase
inhibitors to inhibit each of these kinases during ER stress and test whether it can inhibit
VEGF mRNA up-regulation. The result showed that both p38 MAPK inhibitor
SB203580 and AMPK inhibitor compound C can efficiently inhibit VEGF mRNA upregulation by the UPR without reducing VEGF transcription rate (Figure 2-13); JNK
inhibitor SP600580 inhibits VEGF mRNA up-regulation in response to ER stress and
hypoxia by reducing VEGF transcription (Figure 2-14); while ERK and PI3K inhibitors
do not inhibit the increase of VEGF mRNA (Figure 2-15). This suggests that both p38
MAPK and AMPK play an important role in increasing VEGF mRNA stability while
JNK may increase VEGF transcription rate in response to ER stress. Future studies will
address the specific factors which contribute to up-regulation of VEGF mRNA in more
detail.

Summary
With more evidence of UPR activation in solid tumor, it is now important to
understand what role the UPR plays in tumor survival and growth. In this project, I first
found that several pro-angiogenic factors including VEGF, FGF2, IL-8 and Angiogenin
are induced by UPR activation in the Daoy human medulloblastoma cells in vitro through
a micro-array analysis. To confirm this observation, I did quantitative real-time PCR to
test the level of known UPR targets and of these four pro-angiogenic factors in multiple
cell lines in response to various ER stress inducing agents. I also measured their
induction by hypoxia, which is a well-characterized inducer of pro-angiogenic factors.
All three UPR targets including BiP, CHOP and GRP170 were highly induced in all of
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Figure 2-12. Potential binding sites of UPR downstream transcription factors in VEGF
promoter. An online software, rVista was used to screen potential binding sequences of
transcription factor XBP1 (light blue), ATF4 (green), NFκB (dark blue) and Hif2α (pink)
in 8k upstream promoter region of VEGF gene in human, mouse and rat.
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Figure 2-13. AMPK and p38 MAPK increase VEGF mRNA in response to UPR
activation by increasing its stability. C6 cells were treated with normal condition (Nt),
1% O2 (Hy), thapsigargin (Tg) or no glucose media (No Glu) for 8 hours with no
inhibitor (blue) or with: compound C (red, AMPK inhibitor) or SB203580 (green, p38
MAPK inhibitor). Total RNA was extracted to test VEGF mRNA (A) and VEGF hnRNA
(B) level of each sample. Experiments were performed in duplicate.
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Figure 2-14. JNK increases VEGF mRNA in response to ER stress by increasing its
transcription. C6 cells were treated with normal condition (Nt), 1% O2 (Hy), thapsigargin
(Tg) or no glucose media (No Glu) for 8 hours with no inhibitor (blue) or with: SP600125
(red, JNK inhibitor). Total RNA was extracted to test VEGF mRNA (A) and VEGF
hnRNA (B) level of each sample. Experiments were performed in duplicate.
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Figure 2-15. PI3K and ERK do not increase VEGF in response to UPR activation. C6
cells were treated with normal condition (Nt), 1% O2 (Hy), thapsigargin (Tg) or no
glucose media (No Glu) for 8 hours with no inhibitor (blue) or with: LY294002 (yellow,
PI3K inhibitor) or PD98059 (light green, ERK inhibitor). Total RNA was extracted to
test VEGF mRNA (A) and VEGF hnRNA (B) level of each sample. Experiments were
performed in duplicate.
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the cell lines by ER stress inducers tunicamysin, thapsigargin and no glucose media.
Interestingly, I found that VEGF, IL-8 and Angiogenin were generally up-regulated
during UPR activation in several cell lines including C6 rat glioma cells, NIH3T3 mouse
fibroblast cells, Daoy human medulloblastoma cells, NB1691 and SKNAS human
neuroblastoma cells while FGF2 was only up-regulated in Daoy cells. Furthermore, a
western blot and an ELISA assay demonstrated that VEGF protein and secretion levels
are also increased dramatically during UPR activation. Remarkably, this induction is
even higher than that observed in response to hypoxia treatment, which is known to
potently induce VEGF expression.
To understand the mechanism by which the UPR induces these pro-angiogenic
factors, I chose VEGF expression in C6 cells as my target for further investigation. In
order to test mRNA stability of VEGF under ER stress, an mRNA decay assay was
performed. While the half-life of VEGF under control conditions is less than 30 minutes,
I found that ER stress increased the half-life to ~3 hours. I also measured VEGF hnRNA
levels under control and ER stress conditions as a method to quantify the rate of VEGF
transcription. The data demonstrates that the level of VEGF hnRNA was dramatically
induced in response to ER stress compared to control conditions. Putting these data
together, I demonstrated that the induction of VEGF mRNA under ER stress is due to
both transactivation of VEGF gene and an increase of VEGF mRNA stability. Thus, a
number of UPR downstream transcription factors such as XBP-1, ATF4 and NFκB may
play a role in transactivating the VEGF gene and a group of UPR downstream kinases
may play a role in increasing VEGF mRNA stability through activating ARE binding
protein complex.
We are currently investigating what transcription factors may contribute to
transactivate the VEGF gene. Using rVista, we found binding sequences of several UPR
downstream targets (such as XBP-1, ATF4 and NFκB) within 8k VEGF promoter of both
human and rodent species. Our chromatin IP experiment suggests that XBP-1 may bind
to its binding sites at both -1k and -5k region of VEGF promoter in the C6 cell line. In the
mean time, to determine which kinases contribute to increase VEGF mRNA stability, I
used specific inhibitors for each kinases including JNK, p38 MAPK, AMPK which have
been shown to correlate to the increase of VEGF mRNA stability, and PI3K which has
been shown to up-regulate VEGF transcription, and ERK which should have no effect to
the level of VEGF mRNA. I found that both p38 MAPK inhibitor SB203580 and AMPK
inhibitor compound C can efficiently inhibit VEGF mRNA up-regulation in response to
the UPR without reducing VEGF transcription rate; while JNK inhibitor SP600125 can
inhibit VEGF induction by inhibiting the increase of VEGF transcription. This suggests
that both p38 MAPK and AMPK play an important role in increasing VEGF mRNA
stability, and JNK may up-regulate VEGF transcription in response to ER stress. In
Figure 2-16, we schematically showed how the UPR regulates VEGF mRNA in response
to ER stress in vitro. Future studies will address the specific factors which contribute to
up-regulation of VEGF mRNA in more detail.
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Figure 2-16. Model of UPR pathway regulating VEGF mRNA in C6 cells in vitro.
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Chapter 3. General Discussion
Crosstalk of the UPR and the Hypoxia-induced Response
While plenty of evidence demonstrates that genotoxic mutations are necessary to
transform cancer cells, during rapid tumor growth, a series of cytotoxic conditions, such
as altered pH, low nutrients and hypoxia, can become rate limiting by poorly vascularized
solid tumor cells. These conditions lead to activation of cytoprotective responses
including the UPR (Feldman et al., 2005; Ma and Hendershot, 2004) and the hypoxiainduced response through activation of Hif1α or Hif2α (Graeber et al., 1996; Hockel and
Vaupel, 2001a; Hockel and Vaupel, 2001b). One of the most important pro-angiogenic
factors VEGF has been shown to be induced under hypoxia condition through activation
of Hif1α or Hif2α (Poellinger and Johnson, 2004; Semenza, 2001). In our study and
recent studies from other groups (Drogat et al., 2007; Marjon et al., 2004), VEGF was
also showed to be activated by UPR activation. Our microarray data also suggest that
Hif2α, a well known hypoxia induced transcription factor, was also induced during
thapsigargin induced UPR activation in the Daoy cell line. On the other hand, the proapoptotic tumor suppressor p53 is stabilized during hypoxia through the reduction of
MDM2 (Alarcon et al., 1999), but is destabilized during ER stress due to the
phosphorylation and activation of glycogen synthase kinase-3β (GSK3β) (Qu et al., 2004).
As both pathways can be activated in stressed tumor cells, it is important to know how
the combination of activation of both pathways will regulate their downstream targets. In
one of my experiments, I treated Daoy human medulloblastoma cells with both low
glucose media and hypoxia together. Surprisingly, I found that rather than further
activating the targets which are common to the UPR and the hypoxia induced response,
up-regulation of targets downstream of both pathways, such Hif2α, was delayed and
reduced (Figure 3-1). This suggests that these two pathways may negatively regulate the
activation of each other rather than synergistically activate their targets. However, recent
study from another group observed a higher induction of VEGF when cells were treated
with both low glucose and hypoxia compared to that in single stress treatment in A549/8
human lung carcinoma cells (Drogat et al., 2007). Their data suggest that a target like
VEGF was synergistically activated by both pathways. This contradictionary observation
may be caused by different genotype or celltype of these two cell lines. Further
experiments will characterize the crosstalk of the UPR and the hypoxia induced response
in detail. It will help us to understand how this crosstalk affects tumor progress in vivo.

UPR Activation and Growth of Solid Tumor
While evidence of UPR activation has been shown in several studies, two groups
have recently shown that the UPR is not only activated in solid tumors, but also
contributes to its growth. In 2004, Dr. Albert Koong’s group found that severe hypoxia
(<0.02% O2) can induce XBP1 at the transcriptional level and activate splicing of its
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Figure 3-1. Induction of Hif2α under different stresses. Daoy cells were treated with
regular condition (Nt), thapsigargin (Tg), 0.25M glucose media (LG), 1% O2 (Hy) or
LG+Hy condition. Total cell lysate for each sample was run on SDS gels. Western Blot
for Hif2α was done with rabbit anti-Hif2α antibody. Hsc70 serves as a control.
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mRNA, resulting in increased levels of spliced XBP1 protein (Romero-Ramirez et al.,
2004), which is a typical evidence of ATF6 and IRE1 activation under the UPR (Calfon
et al., 2002; Yoshida et al., 2001). After exposure to hypoxia, they found that apoptosis
increased and clonogenic survival decreased in both XBP-1 knock-out and XBP-1
siRNA-transfected Ras and c-myc transformed MEFs compared to XBP-1 wild type
MEFs. In this study, loss of XBP-1 severely inhibits tumor growth due to inhibition of
the survival of transplanted tumor cells, which strongly suggests that UPR activated
XBP-1 is essential for tumor survival and growth. Later in 2005, Dr. Constantinos
Koumenis’ group found that another UPR branch PERK was activated under extreme
hypoxia (<0.02 O2) and inactivation of PERK pathway by either dominant negative
mutations in PERK or in the translation initiation factor eIF2a impairs cell survival under
extreme hypoxia (Bi et al., 2005). They also found that tumors derived from PERK-/MEFs are much smaller and exhibit higher levels of apoptosis in hypoxic areas compared
to tumors with PERK pathway intact which suggests that PERK branch of the UPR is
important for tumor survival and growth under hypoxia condition. These two studies
clearly indicate that cells in hypoxia region of solid tumors may hijack the UPR pathway
to survive the adverse environment.
In our early study, using microarray analysis we first found that several important
pro-angiogenic factors such as VEGF, IL8 and Angiogenin were induced during UPR
activation in Daoy medulloblastoma cell line. Their induction was further confirmed by
real-time PCR and extended to other cell lines such as C6 rat glioma line, NIH3T3 mouse
fibroblast line, SK-N-AS and NB1691 human neuroblastoma lines. Besides the mRNA
level of these factors, protein and secretion level of VEGF was also dramatically induced
by all tested UPR inducer in C6 cells. We will perform Western Blot and ELISA assays
to test whether VEGF and the other two factors are also induced in each of these cell
lines. Recently, two studies showed that tumor angiogenesis was induced either by PERK
(Blais et al., 2006) or by IRE1 (Drogat et al., 2007). These data strongly implicate that
UPR activation may play an important role in promoting tumor angiogenesis. In future
studies, we will generate genetic mouse model to inhibit each branch of the UPR and test
whether they are important to tumor angiogenesis in vivo.

Evolution of the UPR Pathway
The UPR pathway is present in all eukaryotic organisms and plays an important
role in adapting cells to adverse environment that causes ER stress. In yeast, the whole
UPR pathway is activated by the yeast Ire1 through the cleavage of HAC1 mRNA and
the activation of its encoded transcription factor (Cox and Walter, 1996). This pathway is
required for yeast to survive during ER stress but not during normal cell growth (Cox et
al., 1993; Mori et al., 1993). The function of the UPR in yeast is to increase the
degradative machinery to eliminate unfolded proteins, and to increase the volume and
components of the entire secretory pathway to accommodate its burden and prevent
aggregation of affected proteins (Ma and Hendershot, 2001). In C. elegans, this pathway
is maintained but is supplemented with the PEK pathway, which, based on homology to
mammalian PERK, would be expected to limit protein synthesis during ER stress (Ma
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and Hendershot, 2001). This suggests that, in addition to increase protein degradation and
secretion, higher organisms like C. elegans can also limit its protein synthesis to release
ER stress.
In mammalian cells, the UPR pathway is expanded to four different branches.
Instead of HAC1, IRE1 cleaves XBP-1 mRNA during ER stress in mammalian cells.
This lead to the expression of full-length matured XBP-1 protein (Calfon et al., 2002;
Yoshida et al., 2001) and the up-regulation of its downstream targets such as EDEM,
ERdj3 and ERdj4 (Lee et al., 2003; Yoshida et al., 2003). PERK is also activated during
ER stress. It phosphorylates eIF2α and thus transiently inhibits protein synthesis and
leads to cell cycle arrest due to loss of cyclin D1 (Brewer and Diehl, 2000; Harding et al.,
1999; Shi et al., 1998). In addition to IRE1 and PERK, ATF6 is activated during ER
stress and the transcription factor derived from its cytosolic domain transactivates ER
chaperones BiP, GRP94 and another UPR downstream transcription factor XBP-1
(Yoshida et al., 1998; Yoshida et al., 2001). In addition to these cytoprotective responses,
prolonged or acute ER stress can activate caspase12 in mouse and caspase4 in human and
lead to apoptosis (Hitomi et al., 2004; Nakagawa et al., 2000). Thus, in mammalian, the
UPR pathway can not only protect cells from ER stress by increasing ER capacity,
increasing ER associated degradation (ERAD), limiting protein synthesis and cell cycle
arrest, but also protect the organisms by eliminating severely stressed cells. Importantly,
our data, as well as two recent published studies (Blais et al., 2006; Drogat et al., 2007),
suggest that the UPR pathway may play an important role in promoting tumor
angiogenesis. Our study also indicates that UPR activation may also play a role in
physiological angiogenesis other than that in tumor progress because not only tumor cell
lines, but also NIH3T3 mouse fibroblast cells have increased levels of pro-angiogenic
factors in response to ER stress. If it is the case, our study will originally demonstrate that
the UPR pathway is utilized by mammalian cells not only to defensively protect them
from those adverse environments such as low oxygen, low nutrient and low pH when
cells can not access blood vessels, but also to actively help these cells to resolve the
severe conditions by inducing new blood supply around them.

Implication of UPR Activation in Anti-angiogenic Cancer Therapy
Tumor angiogenesis is regulated by a balance of pro- and antiangiogenic
molecules, and when the balance shifts in favor of angiogenesis inducers, an angiogenic
switch activates the normally quiescent vasculature to develop new blood vessels
(Hanahan and Folkman, 1996). One of the most important pro-angiogenic factors VEGF
has been shown to play an essential role in promoting tumor angiogenesis. A number of
clinical trials are underway to test the utility of anti-VEGF or anti-VEGF receptor
therapies in a variety of cancers. A recent phase III clinical trial demonstrated that
bevacizumab (Avastin), a humanized monoclonal antibody against VEGF-A, in
combination with conventional chemotherapy, increased overall survival by 5 months in
colorectal cancer patients (Hurwitz et al., 2004), leading to FDA approval. However, as
in other anti-cancer therapeutic strategies, apparent resistance to antiangiogenic therapies
has been described in clinical trials and in xenotransplant tumor models (Kerbel et al.,
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2001; Miller et al., 2003; Miller et al., 2005). In one xenograft study, inhibition of
VEGFR2 markedly disrupted angiogenic switching, persistent angiogenesis and initial
tumor growth by inhibiting VEGF signal pathway in the early stage of treatment.
However, in late-stage tumors, phenotypic resistance to VEGFR2 blockade emerged, as
tumors regrew during treatment after an initial period of growth suppression (Casanovas
et al., 2005). They found that this resistance is due to a reactivation of tumor angiogenesis,
independent of VEGF and associated with hypoxia-mediated induction of other proangiogenic factors sunch as FGF2 (Casanovas et al., 2005). As we described in the
previous chapter, several important pro-angiogenic factors were induced by the UPR.
Studies from other groups showed that the UPR is fully activated under extreme hypoxia
(Bi et al., 2005; Romero-Ramirez et al., 2004). Taking together, it suggests that UPR
activation may play a role in the induction of pro-angiogenic factors and the consequent
reactivation of tumor angiogenesis. If this is the case, a strategy combining the antiangiogenic therapy with the inhibition of UPR activation may help diminish the
resistance problem in the late stage of treatment. Thus, a new drug designed to inhibit the
key regulator to pro-angiogenic factors under the UPR may be the next step to approach
the cure of cancer.
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